Search

Satyamaheshwar Peddibhotla

from Orlando, FL
Age ~49
Get Report
Also known as:
Satyamahesh Peddibhotla, Mahesh Peddibhotla, Peddibhotla Satyamaheshwar, S Peddibhotla, W Peddibhotla, L Satyamahes Peddi
Phone and address:
15936 Oak Spring Dr, Orlando, FL 32828
(407) 282-8740
Related to:
Rudra P Adhikari, 65Dorothy Nagle, 76Katharine Nagle, 51David NagleVincent Nagle, 66Sadie Nagleperkins
Connected to:
Bhargavi Peddibhotla, 48Sridevi Peddibhotla, 51Dennis S Peddicord, 77Don B Peddicord, 93Erik T Peddicord, 59Gregory S Peddicord, 38Hilary M Peddicord, 45James N Peddicord, 77Jarvis R Peddicord, 105Jill K Peddicord, 57

Satyamaheshwar Peddibhotla Phones & Addresses

  • 15936 Oak Spring Dr, Orlando, FL 32828 (407) 282-8740
  • East Lansing, MI
  • College Station, TX
  • 15936 Oak Spring Dr, Orlando, FL 32828

Work

Company: Sanford burnham prebys medical discovery institute Sep 2007 Position: Senior scientist

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Michigan State University 1998 to 2004 Specialities: Organic Chemistry

Skills

Medicinal Chemistry • Organic Chemistry • Chemistry • Drug Discovery • Organic Synthesis • Nmr • Hplc • Lc Ms • Protein Chemistry • Chemical Biology • Natural Products • Target Identification • Proteomics • Small Molecules • Purification • Mass Spectrometry • Drug Design • High Throughput Screening • Heterocyclic Chemistry • Characterization • Genetics

Languages

French

Interests

Children • Education • Environment • Science and Technology • Arts and Culture • Health

Industries

Pharmaceuticals

Resumes

Resumes

Satyamaheshwar Peddibhotla Photo 1

Senior Scientist

View page
Location:
Orlando, FL
Industry:
Pharmaceuticals
Work:
Sanford Burnham Prebys Medical Discovery Institute
Senior Scientist
Texas A&M University Jan 2005 - Aug 2007
Post-Doctoral Researcher
Indian Institute of Technology, Bombay 1997 - 1998
Research Associate
Education:
Michigan State University 1998 - 2004
Doctorates, Doctor of Philosophy, Organic Chemistry Indian Institute of Technology, Bombay 1995 - 1997
Master of Science, Masters, Chemistry University of Mumbai 1992 - 1995
Bachelors, Bachelor of Science, Chemistry
Skills:
Medicinal Chemistry
Organic Chemistry
Chemistry
Drug Discovery
Organic Synthesis
Nmr
Hplc
Lc Ms
Protein Chemistry
Chemical Biology
Natural Products
Target Identification
Proteomics
Small Molecules
Purification
Mass Spectrometry
Drug Design
High Throughput Screening
Heterocyclic Chemistry
Characterization
Genetics
Interests:
Children
Education
Environment
Science and Technology
Arts and Culture
Health
Languages:
French

Publications

Us Patents

Nf-Κb Inhibitors And Uses Thereof

View page
US Patent:
7345078, Mar 18, 2008
Filed:
May 30, 2003
Appl. No.:
10/449662
Inventors:
Jetze J. Tepe - East Lansing MI, US
Satyamaheshwar Peddibhotla - College Station TX, US
Assignee:
The Board of Trustees of Michigan State University - Lansing MI
International Classification:
A61K 31/4164
US Classification:
514401, 514402
Abstract:
A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc. ), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-κB as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants.

Multi-Substituted Imidazolines And Method Of Use Thereof

View page
US Patent:
7652056, Jan 26, 2010
Filed:
Apr 6, 2005
Appl. No.:
11/099885
Inventors:
Jetze J. Tepe - East Lansing MI, US
Satyamaheshwar Peddibhotla - Okemos MI, US
Assignee:
Board of Trustees of Michigan State University - Lansing MI
International Classification:
A61K 31/4439
US Classification:
514401, 514341, 514402
Abstract:
A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc. ), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-κB as well as potent activity against the Gram (+) bacterium and with MIC values in the range of 50 μm/mL.

Multi-Substituted Imidazolines And Method Of Use Thereof

View page
US Patent:
7858808, Dec 28, 2010
Filed:
Jan 26, 2010
Appl. No.:
12/694027
Inventors:
Jetze J. Tepe - East Lansing MI, US
Satyamaheshwar Peddibhotla - Okemos MI, US
Assignee:
Board of Trustees of Michigan State University - East Lansing MI
International Classification:
C07D 233/26
US Classification:
5483345
Abstract:
A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc. ), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-κB as well as potent activity against the Gram (+) bacterium and with MIC values in the range of 50 μm/mL.

Multi-Substituted Imidazolines And Method Of Use Thereof

View page
US Patent:
20030232870, Dec 18, 2003
Filed:
Jan 17, 2003
Appl. No.:
10/347323
Inventors:
Jetze Tepe - East Lansing MI, US
Satyamaheshwar Peddibhotla - Okemos MI, US
Assignee:
Board of Trustees of MICHIGAN STATE UNIVERSITY - East Lansing MI
International Classification:
A61K031/4164
C07D233/32
US Classification:
514/401000, 548/322500
Abstract:
A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF- B as well as potent activity against the Gram (+) bacterium and with MIC values in the range of 50 m/mL.

Modulators Of Myocyte Lipid Accumulation And Insulin Resistance And Methods Of Use Thereof

View page
US Patent:
20210300882, Sep 30, 2021
Filed:
Jun 8, 2021
Appl. No.:
17/342187
Inventors:
- La Jolla CA, US
Richard Vega - Orlando FL, US
Hampton Sessions - Orlando FL, US
Teresa Leone - Philadelphia PA, US
Byungyong Ahn - Wallingford PA, US
Satyamaheshwar Peddibhotla - Orlando FL, US
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE - La Jolla CA
International Classification:
C07D 277/46
A61K 31/426
A61K 31/4439
A61K 31/454
A61K 31/496
A61K 31/5377
A61K 31/541
C07D 417/12
A61K 31/5375
A61K 31/428
C07D 295/185
A61P 3/04
A61P 3/10
A61K 45/06
C07D 277/82
C07D 417/04
Abstract:
Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.
Control profile
Satyamaheshwar Peddibhotla from Orlando, FL, age ~49 Get Report